Direkt zum Inhalt
Merck
  • Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.

Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.

Leukemia & lymphoma (2001-06-28)
E Van Den Neste, A Delannoy, W Feremans, A Ferrant, L Michaux
ZUSAMMENFASSUNG

The purine nucleoside analogs fludarabine and 2-chloro-2'-deoxyadenosine display substantial activity in the treatment of various chronic lymphoproliferative disorders. Their major toxicities are primarily immunosuppression and myelosuppression. The profound influence of these drugs on the immune system has raised questions as to the emergence of secondary neoplasms or auto-immune disorders after their use. Based on a literature review and on personal observations, this article reviews the potential clinical importance of these concerns.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
2-Chlor-2′-Desoxyadenosin, antileukemic
Cladribin, European Pharmacopoeia (EP) Reference Standard
Cladribin für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard